Regulatory assessment reveals European Medicines Agency qualification of the hollow fiber system for tuberculosis, indicating its utility in advancing antituberculosis regimen development.
The in vitro hollow fiber system model has been qualified by the European Medicines Agency as a methodology for use in support of selection and development of antituberculosis regimens. More data are expected to be generated in the future to further characterize its value.
No takes yet. Share an insight, caveat, or question.
Cavaleri et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: